GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
Tag Archives: Sativex
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
3 Stocks to Buy if You’re Leery of Buying Marijuana Stocks
Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.
Why Investing in Pot Stocks Will Be So Profitable in 2017
Investing in cannabis stocks is being called the “gold rush” of the 21st century. That’s because legal marijuana sales in North America climbed to $6.7 billion in 2016.
Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches - Sources
GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.
A Biotech Future for Marijuana?
It is often thought that the economic future for recreational marijuana is relatively limited. The people who use it for fun will eventually move from the black market to the legal market.
GWPH Business Plan: Alan Brochstein’s Thoughts
Alan Brochstein has followed quite closely recent developments in the medical and financial world insofar as they have affected GW Pharmaceuticals (NASDAQ: GWPH), the developer of two promising cannabis-based medications.
Are Cannabis Stocks Riding a Market Wave?
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.
Epidiolex Shows Promise for Patients and Investors
The American Academy of Neurology has reported promising results in early trials of the drug, Epidiolex, which is 98 percent pure cannabidiol, in treating severe forms of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.
Equities continued to surge higher and recoup the recent weakness. Keep in mind that just a few days ago, the market was off to its worst start to a calendar year ever.
Study: Adolescents Should Avoid Cannabis
News from Down Under: adolescents should avoid developing cannabis habits according to a recent study. The study examines the sequelae, long-term effects, of adolescent cannabis use on a person from adolescence into young adulthood. The purpose of the study was to look at effects of long-term use, since all other studies on long-term effects had used a piecemeal approach to derive any conclusions.